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Chronic lymphocytic leukemia (CLL) is a common
hematological disorder. Because of its indolent course, pa-
tients with CLL usually do not need immediate treatment and
watch-and-wait is the standard of care in patients with early
stage and asymptomatic CLL.Only patients with late-stage or
symptomatic CLL require antileukemic therapy.1
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article under the CC BY-NC-ND license (http://creativecommons.org/licenseterms “chronic lymphocytic leukemia” AND “bone me-
tastases” OR “bone lesions” OR “bone localization” as
keywords. A total of 54 articles were identified and
reviewed by 2 clinicians. Among them, 7 with therapeutic
options of CLL bone metastases were selected.2-8 Inter-
estingly, none of the papers included ionizing radiation as
a therapeutic option for this condition.
We present the case of a bony localization in a patient
with CLL who was successfully treated with salvage
conformal radiation therapy.Case report
In 2011, a 66-year-old man was diagnosed with CLL,
Rai stage 0, and Binet stage A. The principal characteristicse American Society for Radiation Oncology. This is an open access
s/by-nc-nd/4.0/).
Figure 1 Distal tibial swelling (A). Bone scan with Technetium-99m-methylene diphosphonate, demonstrating early intense uptake in
the distal third of right tibia (B, white arrow).
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blood cell count of 15,800/mm3, lymphocytes 61%, neu-
trophils 32%, monocytes 4%, platelets 141,000/mm3, and
normal hepatic and renal function. Flowcytometric immu-
nophenotyping of the peripheral blood revealed a B-cell
CLL and the following prognostic factors: CD38 negative,
ZAP70 positive, rearrangement of the immunoglobulins
mutated; and FISH: negative. Computed tomography (CT)
scans of the chest/abdomen/pelvis showed the presence of
multiple aortopulmonary and axillary adenopathies
(maximum diameter of 2 cm), and a bone marrow biopsy
showed an infiltration of CLL that was equal to 60% of the
global cellularity.
The patient was observed only until January 2015,
when he was hospitalized for acute anemia (hemoglobin
values, 7.8 g/dl) that required supportive therapy and for
pain in the right foot that was nonresponsive to common
nonsteroidal anti-inflammatory drugs (visual analogue
scale pain score of 8 at the time of diagnosis). It was
decided to re-evaluate the disease as a whole to decide
optimal management. Leukemia was staged again with
instrumental and laboratory tests, which documented the
presence of moderate renal insufficiency (creatine, 2.1
mg/dL), but esophagogastroduodenoscopy, colonoscopy,Figure 2 Right distal tibia bone biopsy (yellow arrows) with hem
paratrabecular proliferation of small lymphocitic elements, apparentl
determining positivity for CD20, CD3 (less than 1 %), CD5, and CDand Coomb’s test results were negative. A bone marrow
biopsy confirmed the diagnosis of CLL with bone marrow
infiltration of 90%. Abdomen ultrasounds showed only
moderate splenomegaly.
In February 2015, because of the persistent pain in the
right foot and the appearance of swelling, a bone scan was
performed, which showed a pronounced osteometabolic re-
action in the distal third of the right tibia. To rule out algo-
dystrophic syndrome, a local biopsy was performed;
surprisingly, a bone localization ofCLLwas detected (Fig 2).
In March 2015, a total body CT scan showed 2 nodular
calcifications in the right lung lobe, multiple right para-
tracheal, aortopulmonary window, and axillary adeno-
pathies. The size of the prostate had also increased. A
subsequent 18F-fluorodeoxyglucose (18F-FDG) positron
emission tomography (PET)/CT scan showed a slight
increase in metabolic activity (standardized uptake value
maximum, 2.2) at the endomedullary tibial distal bone
segment (Fig 3). After a multidisciplinary board, the
patient was referred for a rituximab and bendamustine
chemotherapy regimen with a slow recovery rate of grade
4 thrombocytopenia (23,000/mm3).
The low level of compliance level with this pharma-
cologic approach shifted the therapeutic program toatoxylin and eosin staining, showing monomorphic and diffuse
y with a normal maturation pattern. Immunophentypic analysis
23 and with a Ki-67 of approximately 5%.
Figure 3 Positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose shows, at time of diagnostic
workup, hypermetabolic glucose activity (standardized uptake value maximum, 2.2) at the level of the endomedullary compartment of
the right distal tibia (A, blue arrows). Complete metabolic answer after salvage radiation therapy with an indolent lymphoma dose range
of 24 Gy (B, blue arrows) at 3 months and 17 months (C, blue arrows).
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tion therapy dose was challenging because of a lack of
data in the literature, a dose of 24 Gy in 12 fractions with
a clinical target volume drawn on the PET/CT hyper-
metabolic area and a 2-cm isotropic expansion aimed at
creating the planning target volume was erogated,9 start-
ing with the assumption that leukemic neoplastic and
indolent non-Hodgkin lymphoma cells have similar
radiobiologic features. A re-evaluation PET/CT scan at 3
months and 17 months after the end of radiation therapy
demonstrated the full metabolic response of the lesion
(Fig 3). The patient also showed a very good hemotologic
compensation and clinical response in terms of pain
control and leg swelling (visual analogue scale pain score
0-2 at the subsequent follow-up examinations without use
of antalgic drugs), which did not require any form of
maintenance therapy while continuing with a conservative
observation strategy.Discussion
Bone involvement of CLL is a rare complication that
usually derives fromRichter’s transformation and occurs in
approximately 3% of patients with CLL.8 The lack of evi-
dence for this rare condition became clear after a search of
the English-language literature produced only sporadic
case reports. Unlike the few reports we found in the
English-language literature,2-8 our patient did not show any
sign of hypercalcemia and the anatomical features of the
bone lesion were typical not of a pure osteolytic lesion, but
of an endomedullary permeative lesion with periostium
flogistic involvement. It is also a peculiar event because its
distal appendicular skeleton location is a rare eventuality
that is described mainly at the axial level.
As described by Narayan et al7 in their case report,
chemotherapy with or without radiation therapy
124 C. Tuscano et al Advances in Radiation Oncology: AprileJune 2018consolidation appears to be the most reasonable option for
these patients, considering the similarity to other lym-
phoproliferative disorders such as lymphoma or multiple
myeloma. Chemotherapy also underlines the need for
systemic control of possible undetectable disease. This
line of reasoning is undoubtedly justified, but in selected
patients without systemic signs such as hypercalcemia
and low burden of neoplastic diffusion on morpho-
functional imaging (eg, 18F-FDG PET/CT as in our
case), a local treatment with a lower toxicity charge may
be considered a good option. It is intriguing to presume a
different biologic phenotype,10 and consequently different
growth pathways, between 18F-FDG avid bone lesions
and other classic sites of leukemic disease in which the
glucose metabolism measured with PET scan is normal.
To a certain extent, the bone leukemic spot in our
patient should be considered an independent pathology
that is more similar to a form of indolent lymphoma8 with
excellent radiobiologic features in order to obtain signif-
icant responses with the typical radiation doses around 24
Gy. In selected cases with clinical behaviors that deter-
mine a predominant locoregional invasiveness, this could
give us the opportunity to obtain a good symptomatic
remission that prolongs the period of freedom from more
toxic systemic management strategies. We are aware that
ours is a speculative approach to a very complex matter,
but considering the extreme rarity of this clinical pre-
sentation, we seriously doubt it will be possible to obtain
an evidence-based resolution.
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